Prevalent premalignancy

Abstract

The presence of hematologic malignancy–associated mutations in the blood of individuals without cytopenias or dysplasia has been termed clonal hematopoiesis of indeterminate potential (CHIP), a clinical entity associated with increased age, risk of developing hematologic malignancy, and decreased overall survival.1 Two papers in this issue of Blood take different approaches to advance our understanding of the frequency and clinical characteristics of clonal hematopoiesis. Zink et al analyze whole genome sequencing data from the blood of .11 000 healthy Icelandic individuals, and Buscarlet et al perform targeted sequencing on the blood of 2530 healthy older women.2,3